Bayer's Nexavar disappoints in breast cancer

Share this article:

Bayer and Amgen clocked another failed indication-expansion effort for the cancer drug Nexavar. The companies announced Friday the drug did not hit its Phase-III primary target of improving progression-free survival among patients receiving both Nexavar and chemotherapy. The RESILIENCE study focused on patients with HER2-negative breast cancer who are resistant to, or failed on, taxane therapy or who have failed on anthracycline or for whom anthracycline is not indicated.

The companies also had a setback in March when they announced Nexavar failed to hit the Phase-III target of recurrence-free survival among liver-cancer patients when used as an adjuvant therapy.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.